Latest From Dexcom Inc.
The companies signed a deal to allow Novo Nordisk’s smart insulin pens to share insulin dosing data with Medtronic’s continuous glucose monitoring devices. Novo Nordisk's smart insulin pens are already compatible with all other major brands of continuous glucose monitors.
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
Interoperability and the rising use of continuous glucose monitoring is fueling competition among diabetes device-makers and dominated the conversation at the recent annual ADA meeting.
Investment managing firm Spruce Point says factors such as patients hacking their older Dexcom continuous glucose meters, the company’s decision to not disclose its patient base and competition from Abbott’s upcoming Libre 2 CGMs are red flags that Dexcom is overstating its market potential. Dexcom's stocks lost a fifth of their value after the short-seller released a recent report that says the firm is overvalued.
In Vitro Diagnostics
- Glucose Testing
- Monitoring Equipment & Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Dexcom Inc.
- Senior Management
Kevin Sayer, Pres. & CEO
Jess Roper, SVP, CFO
Richard B Doubleday, Chief Commercial Officer
Jacob Leach, SVP, R&D
Steven Pacelli, EVP, Strategy & Corp. Dev.
- Contact Info
Phone: (858) 200-0200
6340 Sequence Dr.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.